- Home
- GMAB vs KIM Comparison
GMAB vs KIM Comparison
Compare GMAB & KIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- KIM
- Stock Information
- Founded
- GMAB 1999
- KIM 1958
- Country
- GMAB Denmark
- KIM United States
- Employees
- GMAB N/A
- KIM N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- KIM Real Estate Investment Trusts
- Sector
- GMAB Health Care
- KIM Real Estate
- Exchange
- GMAB Nasdaq
- KIM Nasdaq
- Market Cap
- GMAB 17.4B
- KIM 14.1B
- IPO Year
- GMAB N/A
- KIM 1991
- Fundamental
- Price
- GMAB $30.42
- KIM $20.45
- Analyst Decision
- GMAB Strong Buy
- KIM Buy
- Analyst Count
- GMAB 6
- KIM 10
- Target Price
- GMAB $40.40
- KIM $24.20
- AVG Volume (30 Days)
- GMAB 2.4M
- KIM 5.1M
- Earning Date
- GMAB 11-06-2025
- KIM 10-30-2025
- Dividend Yield
- GMAB N/A
- KIM 5.09%
- EPS Growth
- GMAB 132.41
- KIM 57.13
- EPS
- GMAB 25.10
- KIM 0.83
- Revenue
- GMAB $3,845,670,022.00
- KIM $2,123,057,000.00
- Revenue This Year
- GMAB $24.92
- KIM $4.86
- Revenue Next Year
- GMAB $15.97
- KIM $3.18
- P/E Ratio
- GMAB $1.21
- KIM $24.58
- Revenue Growth
- GMAB 29.57
- KIM 8.14
- 52 Week Low
- GMAB $17.24
- KIM $17.93
- 52 Week High
- GMAB $33.65
- KIM $25.83
- Technical
- Relative Strength Index (RSI)
- GMAB 56.40
- KIM 38.67
- Support Level
- GMAB $28.08
- KIM $20.16
- Resistance Level
- GMAB $30.78
- KIM $20.80
- Average True Range (ATR)
- GMAB 0.68
- KIM 0.42
- MACD
- GMAB 0.10
- KIM -0.05
- Stochastic Oscillator
- GMAB 84.63
- KIM 18.60
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.